Bicalutamide 90357-06-5 raw powder High purity 99% High quality

Bicalutamide is a non-steroidal antiandrogen medication primarily used for the treatment of prostate cancer. It functions by competitively inhibiting the androgen receptor, thereby blocking the action of androgens such as testosterone, which are known to promote the growth of prostate cancer cells. Bicalutamide is often used in combination with luteinizing hormone-releasing hormone (LHRH) agonists or surgical castration to enhance its effectiveness. 

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide inhibits human GCGR, GIPR and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively and mouse GCGR, GIPR, and GLP-1R with EC50 values of 2.32, 0.191 and 0.794 nM, respectively. It is an important tool for obesity research.
Retatrutide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GIP receptor (GIPR) or the GLP-1R.
Retatrutide is a synthetic peptide with glucose-lowering effects. It is an antidiabetic agent against type 2 diabetes (T2D), stimulating insulin and suppressing glucagon secretion in a glucose-dependent manner.
Retatrutide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake and reduce body weight in patients with type 2 diabetes.

Remarks: For scientific research or medical use only, not for direct use in humans or as non-medical advice.